Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
Главные авторы: | Lee, M, Beeson, D, Palace, J |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Wiley
2018
|
Схожие документы
-
The congenital myasthenic syndromes.
по: Palace, J, и др.
Опубликовано: (2008) -
Congenital myasthenic syndromes.
по: Beeson, D, и др.
Опубликовано: (1997) -
Congenital myasthenic syndromes: an update.
по: Finlayson, S, и др.
Опубликовано: (2013) -
Congenital myasthenic syndromes and the neuromuscular junction.
по: Cruz, P, и др.
Опубликовано: (2014) -
The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes
по: Rodríguez Cruz, P, и др.
Опубликовано: (2018)